



# Company presentation for investors

Q1-Q3/2013

# Forward-looking statements

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

# Contents

- 4 Results & Outlook Q1-Q3/2013
- 11 Strategy and financial targets
- 15 Orion R&D - long term opportunities
- 22 Proprietary Products and Specialty Products update
- 30 Key financials
- 37 General info





# Results & Outlook

## Q1-Q3/2013

# Key events on Q3 and Q4

- Orion and Hospira have extended their licensing agreement concerning Precedex® in the markets outside the Europe
- Orion and Endo have terminated their collaboration agreement concerning oncology drug research, development and commercialisation
  - Among others, all the rights of ODM-201 revert to Orion
- Investment projects progressing as planned
- Orion signed licence agreement with Janssen for development and commercialisation of its novel treatment for Alzheimer's disease
  - Upfront payment of USD 31 million mainly booked in balance sheet and will be used against Phase IIa costs

# Key figures for Q1-Q3/2013 and FY 2012

	Q1-Q2/13	Q1-Q2/12*	Change %	2012*	2011	Change %
Net sales, EUR million	734.3	726.0	+1.1%	980.4	917.9	+6.8%
Operating profit, EUR million	201.8	219.5	-8.1%	278.3	282.9	-1.6%
% of net sales	27.5%	30.2%		28.4%	30.8%	
R&D expenses, EUR million	72.2	73.9	-2.3%	105.8	87.5	+20.9%
% of net sales	9.8%	10.2%		10.8%	9.5%	
Basic earnings per share, EUR	1.07	1.17	-8.6%	1.47	1.49	-1.3%
Cash flow per share before financial items, EUR	0.56	0.92	-38.9%	1.23	1.10	+12.1%

# Key figures by business areas


Key figures for Pharmaceuticals business	Q1-Q2/13	Q1-Q2/12*	Change %	2012*	2011	Change %
Net sales of Pharmaceuticals, EUR million	<b>693.3</b>	686.8	+0.9%	928.9	870.6	+6.7%
Proprietary Products	<b>285.0</b>	299.9	-5.0%	403.7	408.9	-1.3%
Specialty Products	<b>279.0</b>	269.6	+3.5%	367.2	320.8	+14.4%
Animal Health	<b>52.6</b>	51.6	+1.8%	69.2	67.8	+2.0%
Fermion	<b>46.2</b>	36.4	+26.9%	48.4	43.3	+11.7%
Contract manufacturing and other <sup>1)</sup>	<b>30.6</b>	29.3	+4.5%	40.5	29.7	+36.1%
Pharmaceuticals operating profit, EUR million	<b>205.0</b>	224.3	-8.6%	<b>286.5</b>	287.6	-0.4%
<b>Key figures for Diagnostics business</b>						
Net sales, EUR million	<b>43.4</b>	41.1	+5.6%	<b>54.1</b>	49.5	+9.3%
Operating profit, EUR million	<b>3.9</b>	2.9	+33.0%	<b>2.3</b>	4.9	-51.9%

<sup>1)</sup> Contract manufacturing and other is included in the Pharmaceuticals business segment but is not a separate business division. It is part of the Group's Supply Chain organisation.

# Net sales originate mainly in Europe


Breakdown of EUR 734 million net sales in Q1-Q3/2013

By business division



- Proprietary Products
- Specialty Products
- Animal Health
- Fermion
- Contract manufacturing & Other
- Orion Diagnostica

By market area



- Finland
- Scandinavia
- Other Europe
- North America
- Other Countries

# Best-selling pharmaceuticals

## Orion's best-selling pharmaceuticals, EUR million

	Business Division	Q1–Q3/2013	Q1–Q3/2012	Change %	2012
1. Stalevo <sup>®</sup> , Comtess <sup>®</sup> and Comtan <sup>®</sup> (Parkinson's disease)	PP	156	192	-19%	250
2. Precedex <sup>®</sup> (intensive care sedative)	PP	41	28	+43%	45
3. Simdax <sup>®</sup> (acute decompensated heart failure)	PP	33	32	+3%	44
4. Easyhaler <sup>®</sup> product family (asthma, COPD)	PP	21	20	+3%	27
5. Dexdomitor <sup>®</sup> , Domitor <sup>®</sup> , Domosedan <sup>®</sup> and Antisedan <sup>®</sup> (animal sedatives)	AH	18	16	+10%	23
6. dexdor <sup>®</sup> (intensive care sedative)	PP	18	8	+125%	13
7. Burana <sup>®</sup> (inflammatory pain)	SpP	17	18	-2%	23
8. Marevan <sup>®</sup> (anticoagulant)	SpP	12	12	-3%	16
9. Divina <sup>®</sup> range (menopausal symptoms)	SpP	11	12	-9%	16
10. Trexan <sup>®</sup> (rheumatoid arthritis, cancer)	SpP	9	8	+8%	11
<b>Total</b>		<b>334</b>	<b>347</b>	<b>-4%</b>	<b>467</b>
Share of Pharmaceuticals net sales		<b>48%</b>	<b>50%</b>		<b>50%</b>

■ = Products based on Orion's inventions

PP = Proprietary Products  
SpP = Specialty Products  
AH = Animal Health


# Outlook for 2013 (unchanged)

- **Net sales** will be at similar level to 2012 (net sales in 2012 were EUR 980 million)
- **Operating profit** will be slightly lower than in 2012 (operating profit in 2012 was EUR 278 million\*)
- **Group's capital expenditure** will be about EUR 80 million excluding substantial corporate or product acquisitions (Group's capital expenditure in 2012 was EUR 47 million)




# Orion's strategy and financial targets

# Profitable growth and increased shareholder value whilst keeping business risks under control



# Balancing mid-term – building long-term




# Orion's financial objectives

## Orion's financial objectives are:


- Ensuring financial stability
- Profitable growth

## The objectives are achieved through:


- Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio.
- Maintaining profitability at a good level, the aim being operating profit that exceeds 20% of net sales.
- Keeping the equity ratio at least 50%.



### Operating profit



### Equity ratio and interest-bearing liabilities





# Orion R&D - long term opportunities

# Orion's R&D strategy

## Increased productivity

R&D operational model renewed in 2009

## Focused therapy areas

Focus on three core therapy areas + generics

- Central nervous system diseases
- Oncology and critical care
- Easyhaler pulmonary drugs

## Shared risks and rewards

Emphasis on collaboration and partnerships

- Clinical studies are performed globally, Orion's focus on Europe
- Partnerships are usually sought for clinical phase III at the latest
- Partners are important in marketing authorisation cases in countries outside Europe
- Orion holds the rights for further develop and market the candidate compounds

## Focus on strengths

In-house R&D covers mainly late-stage research and early-stage development phases

- i.e. discovery, preclinical phase and clinical phases I and II

## Diversification


Constant strive to

- Increase the overall number of programmes
- Balance the risks of individual projects
- Acquire new early research molecules
- Improve the life-cycle management of own innovative treatments

## M&As

Active in in-licensing of drug candidates or products

# Collaborative networks across the R&D value chain



# Key clinical pharmaceutical development projects

Project	Indication	Clinical phases			Registration
		I	II	III	
Easyhaler® budesonide-formoterol	Asthma, COPD	●	●	●	○
Stalevo® for Japanese markets <sup>1)</sup>	Parkinson's disease	●	●	●	○
Easyhaler® salmeterol-fluticasone	Asthma, COPD	●	●	○	
ODM-101 (more effective levodopa product)	Parkinson's disease	●	●		
ORM-12741 (alpha-2c adrenoceptor antagonist) <sup>2)</sup>	Alzheimer's disease	●	IIa		
ODM-201 (androgen receptor inhibitor)	Advanced prostate cancer	●	●		
ODM-103 (more effective COMT inhibitor)	Parkinson's disease	○			
ODM-104 (more effective COMT inhibitor)	Parkinson's disease	○			
ODM-102 (alpha-2c adrenoceptor antagonist)	Alzheimer's disease	○			

- 1) Conducted by partner Novartis  
 2) Jointly with Janssen Pharmaceuticals

● Phase completed    ○ = Phase ongoing



ORM-12741,  
alpha-2c  
adrenoceptor  
antagonist

## ORM-12741 - collaboration with Janssen

- Licence agreement announced on 19 December 2013 (includes ORM-12741 and other compounds)
- Orion received USD 31 million upfront payment which will mainly be used against additional Phase IIa study costs
- Orion is eligible to receive milestone payments from Janssen upon successful completion of certain development and commercialization events, as well as royalties on future sales
- Orion has exclusive commercialization rights in Europe
- Janssen has worldwide exclusive license to develop ORM-12741 and an exclusive right to commercialize it outside Europe
- Orion and Janssen will co-fund the development after an additional Phase IIa study is completed successfully by Orion

# ORM-12741 first Phase 2a Study in AD

- Objective
  - To evaluate safety and efficacy of ORM-12741 in treatment of cognitive and behavioral symptoms of Alzheimer's disease
- Design and Methodology
  - Randomised, double-blind, placebo-controlled, parallel-group Phase 2a study in 100 pts
  - Patients with moderately severe Alzheimer's disease (MMSE 12 - 21)
  - Behavioural and psychological symptoms present (NPI  $\geq$  15)
  - All on stable dose of donepezil, rivastigmine or galantamine for at least 3 mo
  - 2 dose levels of ORM-12741 and placebo for 12 weeks as an add-on therapy
- Main Endpoints
  - A battery of computerized neurocognitive tests (CDR System)
    - Pre-specified primary emphasis on composite scores for Quality of Episodic Memory, Quality of Working Memory, Speed of Memory and Power of Attention
  - Neuropsychiatric inventory (NPI)
  - Safety: AEs, vital signs, safety lab, ECG

# ORM-12741 first Phase 2a Study – Conclusions

- Clear positive effects on memory measures on active treatment groups as compared to placebo
  - Clear and statistically significant positive treatment effect on Quality of Episodic Memory (\*p=0.03)
  - Clear and statistically significant positive treatment effect on Quality of Memory (\*p=0.013)
- Clear and statistically significant positive treatment effect on Neuropsychiatric Inventory (NPI) Caregiver Distress score (\*p=0.034)
- Trend for positive treatment effect in Neuropsychiatric Inventory (NPI) total score for the low dose group (\*p=0.12)
- ORM-12741 was generally well tolerated

\*Main treatment effect (used doses: 30-60mg and 100-200 mg)

# ORM-12741 – Next Steps

- A new formulation study followed by
- An additional Phase 2a in AD patients focusing on
  - Confirmation of the first Phase 2a results - especially on NPI
  - Dosing
- Development options for Phase 3

## Cognition

- ✓ Pros': Several compound shown to work, clear study designs, endpoints & regulatory path
- ✓ Cons': Old generic drugs on market, new competitors in pipeline, lower prize expectation than for the latter


## Neuropsychiatric symptoms

- ✓ Pros': Huge unmet need, less competition, high value
- ✓ Cons': Endpoints & regulatory path less clear - need clarification before Phase 3




ODM-201  
a new generation  
androgen receptor  
(AR) inhibitor for  
prostate cancer


# ODM-201 has a unique profile



Enzalutamide  
(MDV-3100)



ARN-509




General chemical structure  
for ODM-201



enzalutamide 19%\*

ODM-201 +  
main metabolite 3% \*\*

ARN-509 29%\*




Compound	AR affinity Ki (nM)	Antagonism WT AR IC50 (nM)	Proliferation VCaP IC50 (nM)
enzalutamide	78	155	400
ARN-509	53	168	300
ODM-201	9	65	500
ORM-15341 (main metabolite)	8	25	600

\*Refs. Clegg et al, Cancer Research 2012; Forster et al, Prostate 2011  
\*\* Rat autoradiography (QWBA confirms brain/plasma ratio of 14C-ODM-201 related radioactivity was 0.04-0.06, indicating negligible penetration to the brain)


- No brain entry
- No CYP inhibition or induction expected with therapeutic doses

# In ARADES I/II study 12 wk PSA response was most pronounced in Chemo-/CYP17i naïve patients


## Chemo-/CYP17i-naïve



## Post-chemo/CYP17i naïve



## Post-CYP17i



**≥ 50% PSA response rate  
86% at 700mg bid**

■ 100 mg bid ■ 200 mg bid ■ 700 mg bid

\*Data truncated at +25%

## Most common (>10%) adverse events in ARADES study by grade

Follow-up until week 12	N of patients (%) (N=124)		
	Grade 1-2	Grade 3	Grade 4
Fatigue /Asthenia	30 (24%)	1 (1%)	-
Back pain	17 (14%)	1 (1%)	-
Constipation	16 (13%)	-	-
Nausea	13 (10%)	1 (1%)	-
Pain	13 (10%)	1 (1%)	-
Decreased appetite	12 (10%)	-	-

- No clear evidence that any observed toxicity is drug related
- No related seizures - one case of convulsion was reported 27 days after stopping treatment
- Safety profile after longer treatment period remains similar

# Conclusions from clinical studies and next steps

- ODM-201 is a safe and well tolerated treatment
  - Adverse events were mostly mild, and seemed to be related to prostate cancer or concomitant diseases
- High response rate in chemo/CYP17i-naïve patients
  - 700 mg bid has the best responses in chemo-/CYP17i-naïve patients. High dose further supported by efficacy data of the formulation bridging study (data to be presented in 2014)
- A Phase 3 study in nmCRPC patients is scheduled to start recruitment in Q2/2014
  - Patients at high risk for developing metastasis as assessed by PSA doubling time
  - To demonstrate the efficacy of ODM-201 for delaying progression to metastatic disease
  - Over 300 sites in more than 20 countries
  - The study was discussed with EMA and FDA as part of end of phase 2 advice process
- Discussions ongoing with partner candidates about other studies (phase 2 and 3)



ODM-101, -103  
and -104 for  
Parkinson's  
disease

# ODM-101, -103 and -104 for Parkinson's disease

## ODM-101, more effective levodopa product

### Phase II Proof of Concept study

- Over 100 patients in Europe
- Key results indicate that ODM-101 is more efficacious than Stalevo
- ODM-101 reduced time periods during the day when patients do not have adequate treatment response
- Press releases: <http://www.orion.fi/ODM-101-PII-press-release>
- <http://www.orion.fi/en/News-and-media/Press-releases2/Archive/2013/3/>

### Next step

- Search for a suitable collaboration approach for the next development phase is ongoing

## ODM-103, more effective COMT-inhibitor

### Pre-clinical study

- Pre-clinical study results indicated that ODM-103 is more effective than entacapone

Phase I Safety study ongoing in Europe since summer 2012


## ODM-104, more effective COMT-inhibitor

### Pre-clinical study

- Pre-clinical study results indicated that ODM-104 is more effective than entacapone

Phase I Safety study ongoing in Europe since summer 2013


Target is to develop the best possible peroral levodopa product to increase premium for market access - improved efficacy / reduced OFF-time





# Proprietary Products and Specialty Products update


# Turning points of Parkinson's franchise



Source: IMS Health 2012

# Rx value shares in USA after generic launches

Total Rx value in USA - all entacapone products




# Precedex has captured a significant market share in the USA

## Sedation market in USA in 2003

Total market value USD 594 million in 2003

- Propofol
- Midazolam
- Dexmedetomidine
- Remifentanyl




Source: IMS Health 2012

## Sedation market in USA in MAT9/2012

Total market value USD 459 million in 2011


- Propofol
- Midazolam
- Dexmedetomidine
- Remifentanyl



# *dexdor*® has growth potential in Europe

## European sedation market MAT6/2013

Total market value EUR 474 million (-0%)



Source: IMS Health MAT6/2013

## Precedex® and *dexdor*® in brief



- API is dexmedetomidine which is a sedative agent originated by Orion's R&D
- Precedex available in more than 30 countries
  - In USA since 2000
  - In Japan since 2004
  - In-market sales USD 270 million in 2012 (+31% YoY)
- *dexdor*® received European marketing authorisation on 16<sup>th</sup> September 2011
  - Launches ongoing
  - Available in 20+ countries
  - Estimated peak sales potential EUR 100 million a year

# Global coverage with well-known Easyhaler device

- Easyhaler® is authorised in 30 countries and coverage expanding, excl. USA and Japan
- Targeting the pulmonologists and general practitioners
- Favorable results from budesonide/formoterol combination development study. Marketing authorisation application submitted in Europe in Q1/2013.
- Fluticasone/salmeterol combination in clinical development (pharmacokinetics)
- Indication in both combinations is asthma (adults and children) and COPD (chronic obstructive pulmonary disease)
- Rights to Easyhaler products repatriated in various European countries




# Retail sales of inhaled respiratory drugs market in Top 5 Europe



# Launches are basis for future growth in SpP

## Specialty Products launches




### SpP launches in 2012

#### By geographic area

Eastern Europe	34
Scandinavia	45
Finland	18
Other	19

#### By product type




Rx	109
OTC/SeCa	7





# Key financials

# Key figures by quarter\*



# Key figures for 2009–Q3/2013

Orion's key figures	2009	2010	2011	2012*	Q1–Q3/2013	Q1–Q3/2012*	Change %
Net sales, EUR million	771.5	849.9	917.9	980.4	734.3	726.0	+1.1%
Operating profit, EUR million	207.0	254.2	282.9	278.3	201.8	219.5	-8.1%
Profit before taxes, EUR million	203.7	252.6	282.0	276.6	199.6	218.5	-8.7%
R&D expenses, EUR million	95.2	85.5	87.5	105.8	72.2	73.9	-2.3%
Equity ratio, %	60.6%	62.7%	64.2%	61.0%	51.5%	58.9%	
Gearing, %	-8.9%	-12.2%	-6.9%	-1.7%	20.5%	7.7%	
ROCE (before taxes), %	37.4%	45.0%	49.4%	45.9%	39.4%	49.9%	
Return on equity, %	35.3%	40.7%	43.3%	41.0%	40.7%	45.6%	
Basic earnings per share, EUR	1.07	1.31	1.49	1.47	1.07	1.17	-8.6%
Cash flow per share before financial items, EUR	1.03	1.26	1.10	1.23	0.56	0.92	-38.9%
Dividend per share, EUR	1.00	1.20	1.30	1.30			
Capital repayment per share, EUR	0.10	0.06	0.12				

# Income Statement 2009—Q3/2013


Formation of profits, EUR million	2009	2010	2011	2012*	Q1—Q3/2013	Q1—Q3/2012*	Change %
Net sales	771.5	849.9	917.9	980.4	734.3	726.0	+1.1%
Cost of goods sold	-265.2	-283.2	-305.1	-350.8	-286.9	-254.4	+12.8%
Gross profit	506.3	566.8	612.8	629.6	447.4	471.6	-5.1%
Other operating income and expenses	6.0	1.2	3.0	6.3	3.4	2.1	+64.2%
Sales and marketing expenses	-160.0	-188.9	-204.8	-206.1	-144.7	-147.8	-2.0%
R&D expenses	-95.2	-85.5	-87.5	-105.8	-72.2	-73.9	-2.3%
Administrative expenses	-50.2	-39.3	-40.6	-45.7	-32.1	-32.5	-1.3%
Operating profit	207.0	254.2	282.9	278.3	201.8	219.5	-8.1%
Profit before taxes	203.7	252.6	282.0	276.6	199.6	218.5	-8.7%
Profit for the period	151.4	184.7	209.5	206.9	150.5	164.5	-8.5%

# Financial position


EUR million	9/13	9/12	Change%
<b>Non-current assets total</b>	<b>352.7</b>	318.2	+10.8%
Inventories	<b>199.6</b>	170.2	+17.3%
Trade receivables	<b>157.9</b>	147.6	+7.0%
Other receivables	<b>43.7</b>	32.3	+35.2%
Money market investments	<b>15.0</b>		
Cash and cash equivalents	<b>157.8</b>	114.3	+38.0%
<b>Current assets total</b>	<b>574.1</b>	464.5	+23.6%
<b>Assets total</b>	<b>926.8</b>	782.7	+18.4%

EUR million	9/13	9/12	Change%
<b>Equity total</b>	<b>477.4</b>	461.1	+3.5%
Interest-bearing non-current liabilities	<b>240.8</b>	119.7	+101.2%
<b>Non-current liabilities total</b>	<b>284.0</b>	161.6	+75.8%
<b>Current liabilities total</b>	<b>165.3</b>	160.0	+3.3%
<b>Liabilities total</b>	<b>449.3</b>	321.6	+39.7%
<b>Equity and liabilities total</b>	<b>926.8</b>	782.7	+18.4%

# Development of Net working capital



- Receivables
- Inventories
- Short-term non-interest bearing liabilities
- Net Working Capital




- Receivables
- Inventories
- Short-term non-interest bearing liabilities
- Net Working Capital

# Dividend distribution

## Dividend distribution policy

Orion's dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives

Dividend distribution history






# General info

# Building well-being is Orion's Mission

Orion is an innovative, European, R&D-based, pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets

Orion in brief	2012
Net sales	EUR 980 million
Operating profit	EUR 278 million
R&D expenses	EUR 106 million
No. of personnel (at end of)	3,486
in Finland	2,783
in other countries	703
Market cap on 31 Dec 2013	EUR 2.9 billion



■ Orion's own sales organisation's areas  
■ Sales areas of partners

# Business divisions



## Proprietary Products

- Patented prescription drugs
- CTAs: CNS, oncology & critical care, Easyhaler pulmonary drugs
- Net sales in 2012 EUR 404 million



## Fermion

- Active pharmaceutical ingredients (API's) for Orion and other companies
- Net sales in 2012 EUR 48 million (excluding supplies for own use)



## Specialty Products

- Generic prescription drugs
- Self-care products
- Net sales in 2012 EUR 367 million



## Contract Manufacturing & Other<sup>1)</sup>

- Pharmaceutical manufacturing for other companies
- Net sales in 2012 EUR 41 million



## Animal Health

- Veterinary medicines and care products for pets and production animals
- Net sales in 2012 EUR 69 million



## Orion Diagnostica

- Diagnostic test systems for point-of-care testing in healthcare and hygiene testing for industry
- Net sales in 2012 EUR 54 million

1) Contract manufacturing and other is included in the Pharmaceuticals business segment but is not a separate business division. It is part of the Group's Supply Chain organisation.

# Market position strengthened in Europe


**Finland**  
Market leader

**Scandinavia**  
Strong domestic market position

**Eastern Europe**  
Branded generics


**Western and Central Europe**  
Strong position with proprietary products

**Southern Europe**  
Progress with proprietary products in hospital markets




# Orion shares are broadly held

By number of shares on 31 Dec



- Households
- Non-Finnish holders and nominee registered
- Private corporations
- Public sector
- Non-profit institutions
- Financial and insurance corporations

By number of votes on 31 Dec




- Households
- Non-Finnish holders and nominee registered
- Private corporations
- Public sector
- Non-profit institutions
- Financial and insurance corporations

Altogether 141.3 million shares and ca. 56,800 shareholders. Both share classes, A and B, are listed on NASDAQ OMX Helsinki since 1 July 2006. A share (ORNAV) has 20 votes/share and B share (ORNBV) has 1 vote/share in the AGM, but they have equal rights to assets and dividends.

# Orion B share performance

3 July 2006— 30 November 2013

Index 3 July 2006 = 100



**Jari Karlson**

CFO

[jari.karlson@orion.fi](mailto:jari.karlson@orion.fi)

+358 10 426 2883

**Tuukka Hirvonen**

Communications Manager

[tuukka.hirvonen@orion.fi](mailto:tuukka.hirvonen@orion.fi)

+358 10 426 2721

**Heidi Ahti**

Executive Assistant (Investor meeting requests)

[heidi.ahti@orion.fi](mailto:heidi.ahti@orion.fi)

+358 10 426 2169

[www.orion.fi/EN/Investors](http://www.orion.fi/EN/Investors)

[twitter.com/OrionCorpIR](https://twitter.com/OrionCorpIR)



# Orion Investor Relations